{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:03:48Z","timestamp":1789970628244,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Johnson & Johnson"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03770-6","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:52:38Z","timestamp":1789969958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Using Pre-Study Patient Interviews to Refine Electronic Patient-Reported Outcomes in Clinical Research of Ustekinumab Induction for Ulcerative Colitis (SIRIUS Study)"],"prefix":"10.1007","clinical-trial-number":[{"clinical-trial-number":"nct04963725","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-181X","authenticated-orcid":false,"given":"Katsumasa","family":"Nagano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1050-4594","authenticated-orcid":false,"given":"Shun","family":"Emoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9565-5404","authenticated-orcid":false,"given":"Yukiko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizue","family":"Sugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2704-054X","authenticated-orcid":false,"given":"Shinichi","family":"Yoshigoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3948-4255","authenticated-orcid":false,"given":"Kunihiro","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2950-7660","authenticated-orcid":false,"given":"Katsuyoshi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"3770_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s43441-019-00034-0","volume":"54","author":"S Stergiopoulos","year":"2020","unstructured":"Stergiopoulos S, Michaels DL, Kunz BL, et al. Measuring the impact of patient engagement and patient centricity in clinical research and development. Ther Innov Regul Sci. 2020;54:103\u201316. https:\/\/doi.org\/10.1007\/s43441-019-00034-0.","journal-title":"Ther Innov Regul Sci"},{"key":"3770_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.4103\/2229-3485.159936","volume":"6","author":"NS Sharma","year":"2015","unstructured":"Sharma NS. Patient centric approach for clinical trials: current trend and new opportunities. Perspect Clin Res. 2015;6:134\u20138. https:\/\/doi.org\/10.4103\/2229-3485.159936.","journal-title":"Perspect Clin Res"},{"key":"3770_CR3","doi-asserted-by":"publisher","first-page":"103604","DOI":"10.1016\/j.drudis.2023.103604","volume":"28","author":"D Amin","year":"2023","unstructured":"Amin D, Vandenbroucke P. Advancing patient-centricity in medical affairs: a survey of patients and patient organizations. Drug Discov Today. 2023;28:103604. https:\/\/doi.org\/10.1016\/j.drudis.2023.103604.","journal-title":"Drug Discov Today"},{"key":"3770_CR4","doi-asserted-by":"publisher","first-page":"e20157","DOI":"10.1016\/j.heliyon.2023.e20157","volume":"9","author":"K Maruszczyk","year":"2023","unstructured":"Maruszczyk K, McMullan C, Aiyegbusi OL, et al. Paving the way for patient centricity in real-world evidence (RWE): qualitative interviews to identify considerations for wider implementation of patient-reported outcomes in RWE generation. Heliyon. 2023;9:e20157. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e20157.","journal-title":"Heliyon"},{"key":"3770_CR5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.cct.2009.02.005","volume":"30","author":"JF Scoggins","year":"2009","unstructured":"Scoggins JF, Patrick DL. The use of patient-reported outcomes instruments in registered clinical trials: evidence from ClinicalTrials.gov. Contemp Clin Trials. 2009;30:289\u201392. https:\/\/doi.org\/10.1016\/j.cct.2009.02.005.","journal-title":"Contemp Clin Trials"},{"key":"3770_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cct.2015.04.004","volume":"43","author":"E Vodicka","year":"2007","unstructured":"Vodicka E, Kim K, Devine EB, et al. Inclusion of patient-reported outcome measures in registered clinical trials: evidence from ClinicalTrials.gov (2007-2013). Contemp Clin Trials. 2007;43:1\u20139. https:\/\/doi.org\/10.1016\/j.cct.2015.04.004.","journal-title":"Contemp Clin Trials"},{"key":"3770_CR7","volume-title":"Users\u2019 guide to integrating patient-reported outcomes in electronic health records","author":"C Snyder","year":"2017","unstructured":"Snyder C, Wu AW. Users\u2019 guide to integrating patient-reported outcomes in electronic health records. Baltimore, MD: Johns Hopkins University; 2017."},{"key":"3770_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMp1611252","volume":"376","author":"E Basch","year":"2017","unstructured":"Basch E. Patient-reported outcomes\u2014harnessing patients\u2019 voices to improve clinical care. N Engl J Med. 2017;376:105\u20138. https:\/\/doi.org\/10.1056\/NEJMp1611252.","journal-title":"N Engl J Med"},{"key":"3770_CR9","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1007\/s11136-013-0390-0","volume":"22","author":"MB Boyce","year":"2013","unstructured":"Boyce MB, Browne JP. Does providing feedback on patient-reported outcomes to healthcare professionals result in better outcomes for patients? A systematic review. Qual Life Res. 2013;22:2265\u201378. https:\/\/doi.org\/10.1007\/s11136-013-0390-0.","journal-title":"Qual Life Res"},{"key":"3770_CR10","doi-asserted-by":"publisher","first-page":"6026","DOI":"10.1038\/s41467-022-33826-4","volume":"13","author":"OL Aiyegbusi","year":"2022","unstructured":"Aiyegbusi OL, Roydhouse J, Cruz Rivera S, et al. Key considerations to reduce or address respondent burden in patient-reported outcome (PRO) data collection. Nat Commun. 2022;13:6026. https:\/\/doi.org\/10.1038\/s41467-022-33826-4.","journal-title":"Nat Commun"},{"key":"3770_CR11","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cgh.2018.12.021","volume":"17","author":"S Restellini","year":"2019","unstructured":"Restellini S, Chao CY, Martel M, et al. Clinical parameters correlate with endoscopic activity of ulcerative colitis: a systematic review. Clin Gastroenterol Hepatol. 2019;17:1265-1275.e8. https:\/\/doi.org\/10.1016\/j.cgh.2018.12.021.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3770_CR12","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.cgh.2019.09.021","volume":"18","author":"C Ma","year":"2020","unstructured":"Ma C, Sandborn WJ, D\u2019Haens GR, et al. Discordance between patient-reported outcomes and mucosal inflammation in patients with mild to moderate ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18:1760-1768.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3770_CR13","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160:1570\u201383. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031.","journal-title":"Gastroenterology"},{"key":"3770_CR14","doi-asserted-by":"publisher","first-page":"e060081","DOI":"10.1136\/bmjopen-2021-060081","volume":"12","author":"K Matsuoka","year":"2022","unstructured":"Matsuoka K, Nagano K, Nagasaki S, et al. Symptom Improvement of ulcerative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study. BMJ Open. 2022;12:e060081. https:\/\/doi.org\/10.1136\/bmjopen-2021-060081.","journal-title":"BMJ Open"},{"key":"3770_CR15","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201\u201314. https:\/\/doi.org\/10.1056\/NEJMoa1900750.","journal-title":"N Engl J Med"},{"key":"3770_CR16","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/j.1369-7625.2012.00795.x","volume":"17","author":"J Brett","year":"2014","unstructured":"Brett J, Staniszewska S, Mockford C, et al. Mapping the impact of patient and public involvement on health and social care research: a systematic review. Health Expect. 2014;17:637\u201350. https:\/\/doi.org\/10.1111\/j.1369-7625.2012.00795.x.","journal-title":"Health Expect"},{"key":"3770_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jama.2017.21903","volume":"319","author":"M Calvert","year":"2018","unstructured":"Calvert M, Kyte D, Mercieca-Bebber R, et al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols. JAMA. 2018;319:483\u201394. https:\/\/doi.org\/10.1001\/jama.2017.21903.","journal-title":"JAMA"},{"key":"3770_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-14-89","volume":"14","author":"JP Domecq","year":"2014","unstructured":"Domecq JP, Prutsky G, Elraiyah T, et al. Patient engagement in research: a systematic review. BMC Health Serv Res. 2014;14:89. https:\/\/doi.org\/10.1186\/1472-6963-14-89.","journal-title":"BMC Health Serv Res"},{"key":"3770_CR19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s13063-021-05255-z","volume":"22","author":"AL Slade","year":"2021","unstructured":"Slade AL, Retzer A, Ahmed K, et al. Systematic review of the use of translated patient-reported outcome measures in cancer trials. Trials. 2021;22:306. https:\/\/doi.org\/10.1186\/s13063-021-05255-z.","journal-title":"Trials"},{"key":"3770_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0810-x","volume":"13","author":"A Slade","year":"2018","unstructured":"Slade A, Isa F, Kyte D, et al. Patient reported outcome measures in rare diseases: a narrative review. Orphanet J Rare Dis. 2018;13:61. https:\/\/doi.org\/10.1186\/s13023-018-0810-x.","journal-title":"Orphanet J Rare Dis"},{"key":"3770_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s40900-015-0008-5","volume":"1","author":"K Staley","year":"2015","unstructured":"Staley K. \u201cIs it worth doing?\u201d Measuring the impact of patient and public involvement in research. Res Involv Engagem. 2015;1:6. https:\/\/doi.org\/10.1186\/s40900-015-0008-5.","journal-title":"Res Involv Engagem"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03770-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:52:39Z","timestamp":1789969959000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03770-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":21,"alternative-id":["3770"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03770-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Katsuyoshi Matsuoka received lecture fees from Johnson & Johnson, Mitsubishi Tanabe Pharma, Takeda, AbbVie, EA Pharma, Pfizer, Mochida, Kyorin, Zeria, Kissei, Nippon Kayaku, Gilead, Eli Lilly, and Bristol-Myers Squibb; research grants from AbbVie, Mochida, JIMRO, and Nippon Kayaku. Yukiko Nishimura received lecture fees and sponsorship from Johnson & Johnson. Kunihiro Nishimura received lecture fees and sponsorship from Johnson & Johnson and Kunihiro Nishimura is CEO and Founder of Xcoo, Inc. Shun Emoto received lecture fees and sponsorship from Johnson & Johnson. Shinichi Yoshigoe, Mizue Sugi and Mizuki Amano are employees of Johnson & Johnson. Katsumasa Nagano has no conflicts of interest. Katsumasa Nagano\u2019s present affiliation is Mitsubishi Research Institute, Inc. At the time of the work reported here, he was affiliated with Johnson & Johnson.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics committee approval was obtained from each facility involved and the non-profit organization MINS Institutional Review Board for the SIRIUS study (Approval number 210211) [\n                      \n                      ]. Ethics committee review for the pre-study patient interviews was waived, as these were conducted as a non-interventional quality-improvement and usability assessment to refine the ePRO questionnaire design and operational procedures for the SIRIUS study. In accordance with the Declaration of Helsinki and the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects, written informed consent was obtained from all participants for participation in the pre-study interviews and for publication of the results in anonymized form. To ensure patient privacy, ASrid did not share any identifiable participants\u2019 data or information linking individual participants to specific statements with the study team. The participants were not asked to provide actual responses to the PRO items collected in the SIRIUS study.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}